Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Rovalpituzumab tesirine (Rova-T), a DLL-3-targeting ADC, failed to improve efficacy outcomes compared with topotecan or as maintenance after first-line therapy in the TAHOE and MERU phase III trials [89,90]
This article has been viewed 1,271,199 times
A5: No, Glutathione Injection requires no downtime
[2] Based on breast milk concentrations from 3 women taking 150 to 200 mg topiramate daily, it was estimated that a breastfed infant (assuming a milk intake of 150 mL/kg/day) would receive approximately 0.1 to 0.7 mg/kg/day or 3% to 23% of the maternal weight-adjusted dose
US$ 21.43
:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)
US$ 27.96
US$ 25.78
US$ 25.70
US$ 24.26
